The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks.

ABSTRACT: The IMI public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) was launched in 2008 with an initial budget of €2 billion. Aiming to accelerate the development of innovative medicines for areas of unmet clinical need, the IMI has committed over €380 million to projects on neurodegenerative disorders (NDD), catalyzing public-private collaborations at scale and at all stages of the R&D pipeline. Because of this vast investment, research on neurodegenerative diseases has made enormous strides in recent decades. The challenge for the future however remains to utilize this newly found knowledge and generated assets to develop better tools and novel therapeutic strategies. Here, we report the results of an integ

SUBMITTER: O'Rourke D 

PROVIDER: S-EPMC9666729 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature